Result of EGM

Evolutec Group PLC 09 November 2005 9 November 2005 EVOLUTEC GROUP PLC ('Evolutec' or 'Company') RESULT OF EGM Evolutec Group plc (AIM: EVC), the biopharmaceutical company developing novel products for the treatment of allergic, inflammatory and autoimmune diseases, is pleased to announce that all of the resolutions at the EGM of the Company, held today, were duly passed. ENDS For further information: Evolutec 0118 922 4480 Mark Carnegie Brown, Chief Executive Officer Nicholas Badman, Chief Financial Officer www.evolutec.co.uk Robert W. Baird 020 7488 1212 Shaun Dobson/Xavier de Mol Notes for Editors: About Evolutec Evolutec, which is based in Reading, UK, is a clinical stage biopharmaceutical company with a focus on allergy, inflammation and auto-immune diseases. The Company has just completed a positive 112 patient proof of concept Phase II clinical trial with rEV131, its lead product, in allergic rhinitis. The company had previously demonstrated clinical activity against the symptoms of rhinitis when rEV131 was delivered as an eye drop. Evolutec intends to carry out additional proof of concept Phase II trials with rEV131 in post-cataract surgery and dry eye. Positive preclinical data has also been generated in asthma. rEV131 is a histamine binding protein and is understood to be the only product currently in clinical trials that impacts the recently discovered H4 receptor, a receptor implicated in many forms of inflammatory disease. The Company has a further two molecules in preclinical development. rEV576, a complement inhibitor that was very effective in a preclinical model of myasthenia gravis, and rEV598, which is being evaluated in carcinoid syndrome and CINV (chemotherapy-induced nausea and vomiting). Evolutec is working with Merial to develop anti-tick and anti-tick borne disease vaccines. Evolutec was founded in 1998 to exploit research carried out by the Natural Environment Research Council. Evolutec's drugs were first isolated from the saliva of ticks but are now manufactured by bacterial fermentation procedures. The tick remains undetected by its hosts, including humans, by injecting an array of molecules into the skin that suppresses normal defence mechanisms. These stealth molecules have evolved over millions of years to enable the tick to take a blood meal from its host. Evolutec employs the tick's evolutionary stealth technology to offer the potential of treating human diseases. Safe Harbour statement: this news release may contain forward-looking statements that reflect the current expectations of the Company regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion of clinical studies, the uncertainties related to the regulatory process, the successful integration of completed mergers and acquisitions and achievement of expected synergies from such transactions, and the ability of the Company to identify and consummate suitable strategic and business combination transactions. This information is provided by RNS The company news service from the London Stock Exchange
UK 100

Latest directors dealings